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Abstract
Mutations in Bruton’s tyrosine kinase (BTK) gene are responsible for X-linked agammaglobulinemia (XLA), which is characterized 
by recurrent bacterial infections, profound hypogammaglobulinemia, and decreased numbers of mature B cells in peripheral blood. 
We evaluated 5 male Brazilian patients, ranging from 3 to 10 years of age, from unrelated families, whose diagnosis was based 
on recurrent infections, markedly reduced levels of IgM, IgG and IgA, and circulating B cell numbers <2%. BTK gene analysis 
was carried out using PCR-SSCP followed by sequencing. We detected three novel (Ala347fsX55, I355T, and Thr324fsX24) 
and two previously reported mutations (Q196X and E441X). Flow cytometry revealed a reduced expression of BTK protein in 
patients and a mosaic pattern of BTK expression was obtained from mothers, indicating that they were XLA carriers.
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X-linked agammaglobulinemia (XLA, MIM# 300755) is 
a rare genetic disorder, which accounts for approximately 
85% of patients with defects in early B cell development 
(1). XLA is characterized by a marked reduction in all serum 
immunoglobulin isotypes with significantly decreased or 
absent B cells, which causes susceptibility to recurrent and 
severe bacterial infections in affected males. 
In 1993, the gene causing XLA was identified as Bruton’s 
tyrosine kinase (BTK) (2,3), which is localized on Xq21.3-
Xq22. BTK encompasses 37.5 kb containing 19 exons (4). 
BTK encodes a multidomain protein composed of five differ-
ent domains: proximal to the N-terminal there is a Pleckstrin 
homology (PH) domain, followed by a Tec-homology (TH), 
a Src-homology 3 (SH3), Src-homology 2 (SH2), and a 
tyrosine kinase domain (SH1) at the C-terminal (3).
More than 800 mutations in BTK have been described 
and have been found in all domains, being spread through-
out the gene (http://bioinf.uta.fi/BTKbase) (5). Mutations in 
BTK can be detected in ~90-95% of males with presumed 
XLA (1). Detection of a BTK mutation is necessary for a 
definitive diagnosis of XLA and subsequent genetic coun-
seling.
The BTK mutations have been reported from many 
different regions (6). Our group has been the only one to 
publish the diagnosis of XLA by analysis of mutations of 
the BTK gene in Brazilian patients (7). In the present study, 
three new BTK mutations are described. 
Material and Methods
Subjects
The patients with XLA presented in this study were 
diagnosed and treated with intravenous immunoglobulin 
replacement. XLA was diagnosed according to the recently 
updated criteria of a World Health Organization scientific 
group for primary immunodeficiency diseases (8): low levels 
of circulating B cells (measured by levels of CD19-positive 
cells in blood samples), decreased or absent immunoglobu-
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lins in serum, and a typical clinical history with recurrent 
bacterial infection or a positive family history. The study was 
approved by the Research Ethics Committee of the State 
University of Campinas (UNICAMP), Campinas, SP, Brazil, 
and all patients gave written informed consent to participate. 
Clinical characteristics, including the levels of immunoglobu-
lins and B cell number, are described in Table 1. 
Flow cytometry analysis of BTK expression
Expression of BTK protein was assessed by flow 
cytometry (9). Briefly, peripheral blood mononuclear cells 
(PBMC) were prepared from venous blood using Ficoll-
Hypaque separation. The PBMC were first stained with 
a phycoerythrin-labeled anti-CD14 (IgG2a; Dako, Japan) 
MoAb to discriminate monocytes. These cells were fixed 
in 4% paraformaldehyde in phosphate-buffered saline for 
15 min at room temperature, permeabilized in 0.1% Triton 
X-100 for 5 min, incubated with 2 µg/mL anti-BTK (48-2H) or 
control IgG1 (Dako) MoAbs for 20 min on ice, washed, and 
then further incubated with a 1:1000 dilution of fluorescein 
isothiocyanate-conjugated goat antimouse IgG1 antibody 
(Southern Biotechnology Associates, Inc., USA) for 20 min 
on ice. The stained cells were analyzed by flow cytometry 
(Epics XL-MCL flow cytometer, Beckman-Coulter, USA).
Detection of BTK mutations 
Genomic DNA was purified from venous blood with a 
Gentra Puregene Blood Kit (Qiagen, USA) and amplified 
with primers encompassing each exon-intron boundary of 
the BTK gene (10). The control samples were obtained from 
healthy adult volunteers. For single-strand conformation 
polymorphism (SSCP) analysis, the amplified products were 
electrophoresed on a polyacrylamide gel and visualized by 
SYBR Gold staining (Invitrogen, USA). When abnormal 
mobility was detected on the SSCP gel, the correspond-
ing exons were sequenced by an automated MegaBACE 
1000 genetic analyzer (GE Healthcare, USA). Because no 
abnormal mobility was detected on SSCP gels for patient 
5, we performed a new screening by SSCP using RT-PCR-
amplified products. Total RNA was extracted from PBMC 
with TRIzol Reagent (Invitrogen) and used for first-strand 
cDNA synthesis. PCR amplification of the cDNA involved 
seven overlapping primers (11). 
Results and Discussion
All patients described in this study developed symptoms 
attributed to immunodeficiency during the first year of life 
and the major clinical manifestation was an increased sus-
ceptibility to respiratory tract infections. The main feature of 
XLA found in all patients was a marked reduction of B cells 
(<1%) and hypogammaglobulinemia before intravenous 
immunoglobulin replacement, as shown in Table 1.
Flow cytometric evaluation of BTK expression in 
monocytes revealed a BTK deficiency (4.5 to 65.2%) in all 
patients (Figure 1). A mosaic pattern of BTK expression in 
monocytes was observed for the mothers, indicating that 
they were XLA carriers. BTK mutations were detected in 
all patients by DNA sequencing.
In P1, a c.718C>T substitution created a stop codon 
(Q196X) in the TH domain, which contains a highly con-
served Zn2+ binding motif and a polyproline stretch (12,13). 
Mutations affecting the Zn2+ binding motif lead to the gen-
eration of unstable protein (12,13). Similarly, the c.1453G>T 
substitution identified in P4 leads to premature termination 
of the protein (E441X) affecting the SH1 kinase domain. 
The kinase domain of BTK has approximately 250 residues 
and a three-dimensional model shows that at the center 
of its catalytic function there are binding sites for ATP and 
substrates that consist of highly conserved residues (14). 
Mutations in the kinase domain should stop the protein 
autophosphorylation activity (9,15). Patients with mutations 
Table 1. Clinical characteristics of our patients with X-linked agammaglobulinemia.
Patient No. Present 
age 
Age at onset Age at 
diagnosisa
Ig levels (mg/dL) at diagnosisb B cells 
(%)
Mutationc Clinical presentation
IgA IgM IgG
P1 3 y 5 m 11 m 18 (33-308) 31 (24-276) 126 (630-2000) 0.1 718C>T Recurrent pneumonia
P2 6 y 3 m   2 y 8 m   1 (90-450) 22 (28-212) 149 (750-1780) 0 1204delT Recurrent pneumonia, 
otitis media
P3 7 y 4 m  1 y 10 m <5.5 (90-450) 19 (28-212) 133 (750-1780) 0.2 1227T>C Pneumococcal meningitis, 
pneumonia, sepsis, 
neurologic sequelae
P4 8 y 1 m  1 y   5 (90-450)   4 (28-212) 3.7 (750-1780) 0 1453G>T Cellulitis, otitis media, 
arthritis, congenital hip 
dislocation
P5 10 y 4 m  2 y 23 (68-500) 26 (30-180)   86 (660-2120) 0.15 1135insT Recurrent pneumonia, 
sinusitis
aAge at the start of intravenous immunoglobulin replacement. bData in parentheses are normal immunoglobulin levels. cNumbering of 
nucleotide position refers to cDNA sequence (GenBank accession No. NM _000061). y = years; m = months.
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in SH1 and significant BTK expression have been reported 
by others (16). 
Patients P2, P3, and P5 had mutations in the SH2 
domain, which recognizes short peptide motifs bearing 
phosphotyrosine residues and links BTK to partner mol-
ecules (17). SH2 mutations should impair the BTK ability 
to induce calcium mobilization and flows from B cell recep-
tor stimulation (18). In P2, a c.1204delT deletion caused 
a frameshift mutation leading to a premature stop codon 
(Ala347fsX55). Similarly, in P5, a c.1135insT insertion 
resulted in the protein change Thr324fsX24. In P3, the 
c.1227T>C mutation resulted in the amino-acid change 
I355T. Due to the possibility of polymorphisms in the BTK 
gene, 100X-chromosomes were evaluated with BtsCI 
restriction enzyme (New England Biolabs, Inc., USA) for 
the c.1227T>C substitution. Since the c.1227T>C mutation 
was not detected in the control samples, the mutation of 
P3 could be confirmed. 
Identification of the molecular defect is an important 
tool for counseling family members at risk of being XLA 
carriers. Samples for carrier detection were obtained from 
three mothers, three grandmothers and 11 maternal aunts 
of patients in the study. All mothers analyzed presented 
heterozygous alleles for the mutations found in their sons, 
but only one grandmother (from P1) was a confirmed XLA 
carrier and none of the maternal aunts had mutations. Ac-
cording to Conley et al. (1), the mother of a patient with 
sporadic XLA has an 80% chance of being a carrier, but 
the maternal grandmother and the maternal aunt are car-
riers only 16 and 25% of the time, respectively. The lower 
frequency is due to the fact that most new mutations occur 
in male gametes (19,20). 
We identified five mutations in BTK during the course of 
our study. Mutations Q196X (P1) and E441X (P4), have been 
reported previously; the remaining three - Ala347fsX55(P2), 
I355T (P3), and Thr324fsX24(P5) - are new. The mutations 
identified lead to deficiency in BTK expression reflecting a 
reduction of mRNA or the instability of protein produced. 
The combined use of genetic analysis and flow cytometric 
assay of BTK protein expression allowed the definitive 
diagnosis of XLA and its detection in carriers.
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